TR
EN
Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19
Abstract
Background: In this study, we aimed to analyze the underlying diseases, laboratory findings and clinical outcomes of elderly patients infected with COVID-19. We also investigated the value of laboratory parameters in the estimation of critical cases and mortality in elderly patients.
Materials and Methods: The study included 314 elderly patients aged 60 years and older who were diagnosed with COVID-19.The patients were divided into two groups according to age, as young old patients (60-74 years) and old old patients (≥75 years). Participants' age, gender, underlying diseases, laboratory findings, disease severity and survival data were obtained from hospital records.
Results: The most common comorbidities in elderly patients were hypertension (57.6%), diabetes mellitus (33.8%) and cardiovascular disease (28%). Old old patients had higher rates of critical type (63.4% vs 30.8%, P<0.001) and death (41.9% vs 21.3%, P<0.001) compared to young old patients. The leukocyte count, neutrophil count, urea, creatinine, C-reactive protein (CRP), procalcitonin, ferritin, troponin T, creatine kinase-MB, prothrombin time and D-dimer values were higher in the old old group compared to the young old group. In contrast, hemoglobin and albumin values were lower in the old old group. The areas under the curve (AUC) of albumin, CRP, procalcitonin, ferritin, troponin T and prothrombin time were greater than 0.80 to predict critically elderly COVID-19 patients. Ferritin had the highest AUC for predicting death (AUC: 0.819) followed by CRP (AUC: 0.805) and procalcitonin (AUC: 0.796).
Conclusions: We found higher rates of critical type and death in old old patients compared to young old patients. In addition, ferritin, CRP, and procalcitonin were strong predictors of both disease severity and mortality in COVID-19-infected elderly subjects.
Keywords
Supporting Institution
YOK
Project Number
YOK
Thanks
We thank Dr. Ayşe Torun and Dr. Reyhan Derya Portakal for assistance in data acquisition.
References
- 1. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6.
- 2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8.
- 3. Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?. Lancet. 2020;395(10230):1111.
- 4. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66-70.
- 5. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-8.
- 6. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2020;1-12.
- 7. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-e18.
- 8. Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et al. Clinical characteristics of older patients infected with COVID-19: A descriptive study. Arch Gerontol Geriatr. 2020;89:104058.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Early Pub Date
April 27, 2023
Publication Date
April 27, 2023
Submission Date
October 8, 2022
Acceptance Date
November 23, 2022
Published in Issue
Year 2023 Volume: 20 Number: 1
APA
Çakırca, G., & Damar Çakırca, T. (2023). Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19. Harran Üniversitesi Tıp Fakültesi Dergisi, 20(1), 19-24. https://doi.org/10.35440/hutfd.1186111
AMA
1.Çakırca G, Damar Çakırca T. Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19. Harran Üniversitesi Tıp Fakültesi Dergisi. 2023;20(1):19-24. doi:10.35440/hutfd.1186111
Chicago
Çakırca, Gökhan, and Tuba Damar Çakırca. 2023. “Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients With COVID-19”. Harran Üniversitesi Tıp Fakültesi Dergisi 20 (1): 19-24. https://doi.org/10.35440/hutfd.1186111.
EndNote
Çakırca G, Damar Çakırca T (April 1, 2023) Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19. Harran Üniversitesi Tıp Fakültesi Dergisi 20 1 19–24.
IEEE
[1]G. Çakırca and T. Damar Çakırca, “Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19”, Harran Üniversitesi Tıp Fakültesi Dergisi, vol. 20, no. 1, pp. 19–24, Apr. 2023, doi: 10.35440/hutfd.1186111.
ISNAD
Çakırca, Gökhan - Damar Çakırca, Tuba. “Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients With COVID-19”. Harran Üniversitesi Tıp Fakültesi Dergisi 20/1 (April 1, 2023): 19-24. https://doi.org/10.35440/hutfd.1186111.
JAMA
1.Çakırca G, Damar Çakırca T. Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19. Harran Üniversitesi Tıp Fakültesi Dergisi. 2023;20:19–24.
MLA
Çakırca, Gökhan, and Tuba Damar Çakırca. “Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients With COVID-19”. Harran Üniversitesi Tıp Fakültesi Dergisi, vol. 20, no. 1, Apr. 2023, pp. 19-24, doi:10.35440/hutfd.1186111.
Vancouver
1.Gökhan Çakırca, Tuba Damar Çakırca. Evaluation of Comorbidities, Laboratory Findings and Clinical Outcomes in Elderly Patients with COVID-19. Harran Üniversitesi Tıp Fakültesi Dergisi. 2023 Apr. 1;20(1):19-24. doi:10.35440/hutfd.1186111